PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study
EuroIntervention 2010;6:220-226.
Yves-Laurent Bayard1, MD; Heyder Omran2, MD; Petr Neuzil3, MD; Leif Thuesen4, MD; Maximilian Pichler5, MD; Edward Rowland6, MD; Angelo Ramondo7, MD; Witold Ruzyllo8, MD; Werner Budts9, MD; Gilles Montalescot10, MD; Pedro Brugada11, MD; Patrick W. Serruys12, MD; Alec Vahanian13, MD; Jean-François Piéchaud14, MD; Antonio Bartorelli15, MD; Jean Marco16, MD; Peter Probst17, MD; Karl-Heinz Kuck18, MD; Stefan H. Ostermayer1, MD; Fra
1. CardioVascular Center Frankfurt, Sankt Katharinen, Frankfurt, Germany; 2. Sankt Marien Hospital, Academic Center of the University of Bonn, Bonn, Germany; 3. Na Homolce Hospital, Prague, Czech Republic; 4. Skejby Sygehus, Aarhus, Denmark; 5. Landeskran
Aims: The European PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) study was performed to determine the safety and efficacy of left atrial appendage occlusion by cathete